Category - Developments

Developments

Soricimed, Mount Allison University to collaborate on novel biopesticide solution

Closely-held Soricimed Biopharma and Dr. Vett Lloyd, a professor in the Biology Department at Mount Allison University and head of the Lloyd Tick Lab, are collaborating to design a species-specific, microbial...

November 9, 2021

Developments

BerGenBio presents bemcentinib data in NSCLC; receives FDA fast track

BerGenBio ASA (OSE:BGBIO) will deliver an e-poster presentation at the online Society for Immunotherapy of Cancer meeting with preclinical and clinical data suggesting that bemcentinib restored response to anti-PD-1...

November 9, 2021

Developments

POINT Biopharma, IONETIX in Ac-225 supply agreement

POINT Biopharma Global (NASDAQ:PNT) and IONETIX, a leading cyclotron technology and isotope manufacturing company, entered into a long-term supply agreement for actinium-225 (Ac-225) to support POINT’s validation, drug...

November 9, 2021

Developments

UNITY posts positive Phase 1 data in advanced vascular eye disease

UNITY Biotechnology (NASDAQ:UBX) announced positive 24-week data from its Phase 1 single ascending dose safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet age-related...

November 9, 2021

Developments

RNADD in exclusive license for RNA-based molecular lateral flow assay technology

RNA Disease Diagnostics (RNADD) secured an exclusive global license to a rapid ribonucleic acid-based molecular lateral flow assay (LFA) technology jointly owned by the University of Maryland, Baltimore (UMB) and the...

November 9, 2021

Developments

Sustained anti-pruritic effect of Titan’s TP-2021 implant featured at Neuroscience conference

In a presentation at the Society for Neuroscience 2021 meeting, Ben Land, Ph.D., research assistant professor at the University of Washington’s Department of Pharmacology, reported additional positive data from an...

November 8, 2021

Developments

TransMedics posts positive results from randomized OCS DCD heart trial

TransMedics Group (NASDAQ:TMDX) reported positive topline results from its OCS donors after circulatory death (DCD) heart trial. The OCS DCD heart trial was designed as the first and only randomized trial to compare...

November 4, 2021

Developments

Activ Surgical completes first In-human study of surgical intelligence and sensing platform

Closely-held Activ Surgical, a digital surgery pioneer, completed of its first-in-human surgery clinical trial utilizing the company’s technology-as-a-service bundle: the ActivInsights augment reality (AR)-based...

November 3, 2021

Developments

Clene fails to meet endpoints in Phase 2 RESCUE-ALS clinical trial

Top-line data from Clene’s RESCUE-ALS, a Phase 2 clinical trial evaluating CNM-Au8 as a disease modifying treatment for people with early amyotrophic lateral sclerosis (ALS), failed to meet the primary or...

November 2, 2021

Developments

FDA grants Sio Gene fast track for gene therapy for GM2 gangliosidosis

Sio Gene Therapies (NASDAQ:SIOX) received fast track designation for AXO-AAV-GM2, an investigational gene therapy for the treatment of early infantile, late infantile, and juvenile-onset Tay-Sachs and Sandhoff disease...

November 1, 2021

Category - Developments

Soricimed, Mount Allison University to collaborate on novel biopesticide solution

BerGenBio presents bemcentinib data in NSCLC; receives FDA fast track

POINT Biopharma, IONETIX in Ac-225 supply agreement

UNITY posts positive Phase 1 data in advanced vascular eye disease

RNADD in exclusive license for RNA-based molecular lateral flow assay technology

Sustained anti-pruritic effect of Titan’s TP-2021 implant featured at Neuroscience conference

TransMedics posts positive results from randomized OCS DCD heart trial

Activ Surgical completes first In-human study of surgical intelligence and sensing platform

Clene fails to meet endpoints in Phase 2 RESCUE-ALS clinical trial

FDA grants Sio Gene fast track for gene therapy for GM2 gangliosidosis

General

More